Virpax Pharmaceuticals, Inc.
VRPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $0 | $0 | $0 |
| G&A Expenses | $6 | $0 | $0 | $0 |
| SG&A Expenses | $6 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $0 | $0 | $0 |
| Operating Income | -$12 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$12 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -2,836.41 | -12.97 | -18.32 | -10.37 |
| % Growth | -21,769% | 29.2% | -76.7% | – |
| EPS Diluted | -2,836.41 | -12.97 | -18.32 | -10.37 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |